NEW YORK, June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today ...
- ISB 2001 is a first-in-class T cell-engaging (TCE) trispecific antibody based on Ichnos' proprietary BEAT ® platform that targets BCMA and CD38 on multiple myeloma (MM) cells. - ISB 2001 exhibited ...
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM Company will also present safety and tolerability data from Phase 1/2 study of ...
No dose-limiting toxicities were observed up to weekly subcutaneous doses of 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and no discontinuations due to adverse ...
Article highlights preclinical findings demonstrating ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity Data show superior killing potency of ...
TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy NEW YORK, June 2, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results